AstraZeneca ditches lung cancer treatment trial
Drug giant AstraZeneca has revealed its latest setback in just over a month after halting a late stage lung cancer treatment trial. The FTSE 100 firm said it found its Volrustomig drug, when combined with chemotherapy, was unlikely to boost survival rates for lung …